Chemistry: molecular biology and microbiology – Process of mutation – cell fusion – or genetic modification – Introduction of a polynucleotide molecule into or...
Reexamination Certificate
2000-06-29
2002-07-02
Yucel, Remy (Department: 1636)
Chemistry: molecular biology and microbiology
Process of mutation, cell fusion, or genetic modification
Introduction of a polynucleotide molecule into or...
C435S006120, C435S091100, C530S350000, C536S023100
Reexamination Certificate
active
06413775
ABSTRACT:
FIELD OF THE INVENTION
This invention relates generally to the field of anti-tumor therapies. More particularly, this invention provides a method for enhancing the anti-tumor potency and selectivity of certain polyamine analogs. Viewed alternatively, it may be regarded as a drug activated suicide gene therapy.
DESCRIPTION OF RELATED ART
The polyamine analog N
1
, N
11
diethylnorspermine (DENSPM,
FIG. 1
) is currently undergoing clinical evaluation against various solid tumors (Bergeron et al., 1997, J. Med. Chem. 40: 1475-1494; Porter et al., 1992
, Falk Symposium on Polyamines in the Gastrointestinal Tract
, Edited by R. H. Dowling, U. R. Folsch, and Chr Loser, Kluwer Academic Publishers, Dordrecht, 1992, pp. 301-322). Under in vitro growth inhibitory conditions, the analog depletes polyamine pools by down-regulating the key polyamine biosynthetic enzymes, ornithine and S-adenosylmethionine decarboxylase, and potently up-regulating the polyamine catabolic enzyme, spermidine-spermine N
1
-acetyltransferase (SSAT). In many tumor cells, induction of SSAT activity may exceed 1000-fold and this may represent the most potent gene response to any small molecule anticancer agent. Because polyamines, and particularly spermidine, are required for cell growth (Mamont et al., 1978, Biochem. Biophys. Res. Commun. 81:58-66; Kramer et al., 1989, Biochem J. 259:325-331) antiproliferative strategies designed to selectively deplete these molecules from cancer cells have emerged as experimental anticancer therapies (Marton and Pegg, Ann. Rev. Pharmacol. 195, 35:55-91). Induction of SSAT now appears to be a novel means to achieve polyamine pool depletion.
Potent induction of SSAT by DENSPM has been known for some time (Porter et al., supra; Casero et al., 1989
, Cancer Res
., 49:3829-3833) and several groups have attempted to determine the role of this response in analog mediated growth inhibition. Several lines of evidence support the relationship between SSAT induction and inhibition of cell growth. It is known that both polyamine pool depletion and cell growth inhibition of various cell lines by DENSPM correlates with the extent to which SSAT is induced (Casero et al., 1989, supra; Porter et al., 1991
, Cancer Res
. 51:3715-3720, 1991; Shappell et al., 1992
, Anticancer Res
. 12:1083-1090). Analogs that differentially induce SSAT within a single cell line, inhibit cell growth in a manner that is highly correlative with enzyme induction Porter et al., 1991, supra; Kramer et al., 1999
, Cancer Res
. 59:1278-1286). In other studies, murine embryonic fibroblasts derived from transgenic mice that systemically overexpress SSAT were observed to be more growth sensitive to DENSPM than those from parental animals (Pietilä et al., 1997, J. Biol. Chem. 272:18746-18751; Alhonen et al., 1998, J. Biol. Chem. 273:1964-1969). Finally, DENSPM resistant CHO cells have been shown to be unable to induce high levels of SSAT activity (McCloskey et al., 1999
, Proc. Am. Assoc. Cancer Res
. 40:302).
While the above observations suggest that induction of SSAT is correlated with inhibition of cell growth, stable over-expression of SSAT does not appear to affect growth rate. It was observed that fibroblasts from transgenic mice that overexpress SSAT, grew at approximately the same rate as parental fibroblasts. A similar observation was recently made with CHO cells transfected with SSAT (McCloskey et al., 1999, J. Biol. Chem. 274, 6174-6182).
Thus, the role of SSAT in growth inhibition at the time of the studies described below was uncertain and despite the known inhibitory effects of DENSPM, in the absence of a clear understanding of the role of SSAT, its anti-tumor effects have not been fully elucidated. Such information could provide valuable strategies for the use and development of polyamine analogs as novel anti-tumor therapies. More particularly, induction of SSAT would provide a useful alternative to the use of polyamine inhibitors and analogs as a novel means to deplete intracellular polyamine pools and inhibit cell growth.
SUMMARY OF THE INVENTION
The present invention discloses a method for increasing the anti-tumor potency and selectivity of DENSPM, a polyamine analog. The present method is based on the unexpected observation that increasing the amount of SSAT mRNA, depletes certain polyamine pools, inhibits cell growth and significantly increases the effectiveness of DENSPM. In one embodiment of the invention, SSAT activity is increased by conditional overexpression of SSAT mRNA. In another embodiment, SSAT activity is increased by using a polyamine analog to markedly enhance the expression of the endogenous SSAT gene.
An object of the present invention is to increase the antitumor effectiveness of DENSPM by overexpressing SSAT MRNA prior to treatment with the analog.
Another object of the present invention is to increase the effectiveness of DENSPM by the use of drugs, radiation or factors that enhance transcription of the endogenous SSAT gene.
Another object of the present invention is to provide a conditionally activated gene therapy wherein the induction of SSAT is placed under the control of tissue-specific gene promoter, followed by treatment with DENSPM.
REFERENCES:
Parry et al. Post-transcriptional regulation of the content of spermidine/spermine N1-acetyltransferase by N1N12-bis(ethyl)spermine 1995.*
Parry et al, Post-transcriptional regulation of the content of spermidine/spermine N1-acetyltransferase by N1N12-bis(ethyl)spermine, Biochem J. (1995), 451-452 (1995).*
Robbins, Paul D. et al, Viral Vectors for Gene Therapy, Pharmacol. Ther., vol. 80, No. 1, 1998, p. 41.*
Friedman, Theodore, Overcoming the Obstacles, Scientific American, Jun. 1997, pp. 99-100.*
Schofiel, J. P. et al, Non-viral Approaches to Gene Therapy, British Medical Bulletin, vol. 51 No. 1, 1995, p. 63.*
Amundson et al, Fluorescent cDNA microarray hybridization reveals complexity and heterogeneity of cellular genotoxic stress responses, Onocogene, vol. 18, 1999.*
CAS Registry, No. 121749-39-1, N1, N11 diethylnorspermine.*
CAS Registry, No. 61345-84-4, N1, N12 bis(ethyl)spermine.*
Bergeron, et al, 1997, J. Med. Chem. 40:1475-1494.
Porter, et al, 1992, Falk Symposium on Polyamines in the Gastrointestinal Tract, Edited by R.H. Dowling, U.R. Fosch, and Chr. Loser, Kluwer Academic Publishers, Dordrecht, 1992, pp. 301-322.
Casero, et al, 1989, Cancer Res., 49:3829-3833.
Porter, et al, 1991, Cancer Res. 51:3715-3720, 1991.
Shappell, et al, 1992, Anticancer Res. 12:1083-1090.
Pietilä, et al, 1997, J. Biol. Chem . 272:18746-18751.
Alhonen, et al, 1998, J. Biol. Chem. 273:1964-1969.
McCloskey, et al, 1999, J. Biol. Chem. 274, 6175-6182.
Kee Kristen
Kramer Debora
Porter Carl W.
Vujcic Slavoljub
Health Research , Inc.
Hodgson & Russ LLP
Katcheves Konstantina
Yucel Remy
LandOfFree
Polyamine analog-activated SSAT gene therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polyamine analog-activated SSAT gene therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polyamine analog-activated SSAT gene therapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2844976